Search form

Search form

A study of Illinois residents showed people living in urban areas were more likely than their rural or suburban counterparts to get a diagnosis of breast, colorectal, lung or prostate cancer later in the disease's progression. Chicagoans had the highest rates of late-stage cancer diagnoses. Researchers said more urban-based programs are needed for education and screening, especially for vulnerable groups.

Related Summaries

Women are more likely to be diagnosed with breast cancer at a later stage of the disease's progression if they are uninsured or live in poor neighborhoods, research shows. The research team compared census data with information on 161,619 patients from cancer registries in several states. "In all these states, we looked at every woman ever diagnosed with late-stage breast cancer [age 40 and older] between 2004 and 2006," said Kevin Henry, an assistant professor of geography at the University of Utah.

Eli Lilly's experimental drug ramucirumab met the main endpoint of improved overall survival and the secondary goal of extended progression-free survival in patients with metastatic gastric cancer in a late-stage trial. Lilly said the findings boosts its confidence in ramucirumab, which is in six late-stage trials for breast, gastric, colorectal, lung and hepatocellular cancers.

A Journal of the National Cancer Institute study found men are being diagnosed with prostate cancer earlier, at about age 67 in 2004-2005, compared with age 72 in the late 1980s. Researchers said the rate of late-stage diagnoses have decreased as well.

Genentech reported interim findings from a late-stage study showing that the combination of its drugs Avastin and Tarceva significantly prolonged survival in people with nonsmall-cell lung cancer without disease progression. The results prompted Genentech to halt the trial, indicating that the combination's "clinical benefit is likely quite significant," an analyst said.

Genentech reported interim findings from a late-stage study showing that the combination of its drugs Avastin and Tarceva significantly prolonged survival in people with nonsmall-cell lung cancer without disease progression. The results prompted Genentech to halt the trial, indicating that the combination's "clinical benefit is likely quite significant," an analyst said.